14248-71-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Ethoxynicotinonitrile 98%3-CYANO-2-ETHOXYPYRIDINE is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure and reactivity make it a valuable component in the development of new drugs and medications.
Used in Agrochemical Production:
In the agrochemical industry, 2-Ethoxynicotinonitrile 98%3-CYANO-2-ETHOXYPYRIDINE is used as a key ingredient in the production of pesticides and other agrochemicals. Its properties contribute to the effectiveness and performance of these products, helping to protect crops and enhance agricultural yields.
Used in Food Industry:
2-Ethoxynicotinonitrile 98%3-CYANO-2-ETHOXYPYRIDINE is used as a flavoring agent or a component in food additives. Its unique chemical properties allow it to contribute to the taste, aroma, or appearance of various food products, enhancing the overall consumer experience.

InChI:InChI=1/C8H8N2O/c1-2-11-8-7(6-9)4-3-5-10-8/h3-5H,2H2,1H3

Upstream product

• 52200-48-3 3-bromo-2-chloropyridine 
• 20577-27-9 2-hydroxy-3-cyanopyridine 
• 64-17-5 ethanol 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 557-21-1 zinc(II) cyanide 
• 57883-25-7 3-bromo-2-ethoxypyridine 

Downstream Products

• 851773-43-8 (2-ethoxypyridin-3-yl)methanamine 

Relevant academic research and scientific papers

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H-1,2,4-triazol-3-one, by Fragment-Based Drug Design

This publication details the successful use of FBDD (fragment-based drug discovery) principles in the invention of a novel covalent Bruton's tyrosine kinase inhibitor, which ultimately became the Takeda Pharmaceuticals clinical candidate TAK-020. Describe

MACROCYCLES AS PDE1 INHIBITORS

The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE

A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).